newsfilter
← Latest News
PR Newswire·

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date Topline data from NIH-supported Phase 2 clinical trial for advanced